SCHEMBL6574325

SCHEMBL6574325

Cc1ccc(NS(=O)(=O)c2c(C)c(C)cc(C)c2C)cc1NC(=O)Cc1ccc(C#N)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.44
HTT P42858 2/20 0.44
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.44
RORC P51449 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
IDO1 P14902 1/20 0.42
KDM1A O60341 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
IDH1 O75874 1/20 0.39
MAPT P10636 1/20 0.39
BRD4 O60885 1/20 0.39
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
HSD17B10 Q99714 1/20 0.38
BRPF1 P55201 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6766536 0.86 HDAC1 (0.52) LMNARORCKDM1AMEN1KMT2A
SCHEMBL6571783 0.83 LMNA (0.51) LMNAMAPK1RORCSMN1; SMN2IDO1
SCHEMBL6767804 0.83 SMN1; SMN2 (0.54) LMNAHTTGAAMAPK1SMN1; SMN2
SCHEMBL6574056 0.81 RORC (0.45) LMNARORCIDO1IDH1ALDH1A1
SCHEMBL6765129 0.80 MGAT2 (0.56) LMNARORCKDM1ABRD4ALDH1A1
SCHEMBL6571948 0.79 HDAC1 (0.48) LMNAHTTGAARORCIDO1
SCHEMBL6574032 0.79 HIF1A (0.43) LMNAHTTGAAMAPK1RORC
SCHEMBL6762133 0.78 POLB (0.53) LMNARORCKDM1AMEN1KMT2A
SCHEMBL6572898 0.76 IDH1 (0.40) LMNARORCIDO1IDH1ALDH1A1
SCHEMBL6569935 0.75 MCL1 (0.49) LMNAHTTGAARORCIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040248897-A1 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-12-09 US disclosed
EP-1414790-A1 SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-05-06 EP disclosed
WO-2003000653-A1 SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248897-A1 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions NAT1, CYP3A5, CYP3A7 LMNA 1447/4885HTT 3073/4885GAA 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.